ArticleCurrent infectious disease reports2007
Macrolide immunomodulation of chronic respiratory diseases.
Article in Current infectious disease reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Macrolides usage as anti-inflammatory agents in the treatment of community-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.Reviews in medical virology · 2022Pooled it
- "The effect of 48-weeks azithromycin therapy on levels of soluble biomarkers associated with HIV-associated chronic lung disease".International immunopharmacology · 2023Trial
- Diffuse panbronchiolitis in children misdiagnosed as asthma: A case report.World journal of clinical cases · 2025Article
- Treatment Strategy of Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Review of Recent Evidence.International journal of molecular sciences · 2023Review
- Administration of macrolide antibiotics increases cardiovascular risk.Frontiers in cardiovascular medicine · 2023Article
- Review
- Azithromycin use and outcomes in severe sepsis patients with and without pneumonia.Journal of critical care · 2016Article
- The challenge of chronic lung disease in HIV-infected children and adolescents.Journal of the International AIDS Society · 2013Review
- Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia.Intensive care medicine · 2013Article
- Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.European journal of clinical pharmacology · 2012Review
- Macrolides in chronic inflammatory skin disorders.Mediators of inflammation · 2012Review
- Combination antibiotic treatment of severe community-acquired pneumonia.Current infectious disease reports · 2011Article
- The role of macrolides in noncystic fibrosis bronchiectasis.Pulmonary medicine · 2011Article
- Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune System.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.Intensive care medicine · 2010Article
- Does Ureaplasma spp. cause chronic lung disease of prematurity: ask the audience?Early human development · 2009Article
- Azithromycin use prior to ICU admission is associated with a lower short-term mortality for critically ill acute exacerbations of chronic obstructive pulmonary disease patients: A retrospective cohort study.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Important immunomodulatory properties of 14- and 15-membered macrolides may benefit patients with respiratory diseases associated with chronic inflammation. These properties include decreased neutrophil chemotaxis and infiltration into the respiratory epithelium, inhibition of transcription factors leading to decreased proinflammatory cytokine production, downregulation of adhesion molecule expression, inhibition of microbial virulence factors including biofilm formation, reduced generation of oxygen-free radicals, enhanced neutrophil apoptosis, and decreased mucus hypersecretion with improved mucociliary clearance. Chronic, low-dose macrolides have dramatically improved survival in patients with diffuse panbronchiolitis (DPB). Given the overlap in pathogenesis between DPB and other chronic respiratory diseases, macrolides are being investigated for cystic fibrosis, asthma, chronic bronchitis, chronic sinusitis, and chronic obstructive pulmonary disease. Preliminary data (largely from open-label trials) are promising, but conclusive results are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.